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A pathogenic haplotype, common 
in Europeans, causes autosomal 
recessive albinism and uncovers 
missing heritability in OCA1
Karen Grønskov  1, Cathrine Jespersgaard1, Gitte Hoffmann Bruun2, Pernille Harris3, 
Karen Brøndum-Nielsen1, Brage S. Andresen  2 & Thomas Rosenberg  4
Oculocutaneous albinism (OCA) is a genetically heterogeneous disorder. Six genes are associated 
with autosomal recessive OCA (TYR, OCA2, TYRP1, SLC45A2, SLC24A5 and LRMDA), and one gene, 
GPR143, is associated with X-linked ocular albinism (OA). Molecular genetic analysis provides a 
genetic diagnosis in approximately 60% of individuals with clinical OA/OCA. A considerably number 
of the remaining 40% are heterozygous for a causative sequence variation in TYR. To identify missing 
causative sequence variants in these, we used a NGS based approach, genotyping and segregation 
analysis. We report two putative pathogenic haplotypes which only differ by two extremely rare SNVs, 
indicating that the haplotypes have a common derivation. Both haplotypes segregate consistent with 
an autosomal recessive inheritance pattern and include the allele p.S192Y-p.R402Q. An explanation for 
the pathogenicity of the haplotypes could be the combination of p.S192Y and p.R402Q. Homozygosity 
for the pathogenic haplotypes causes a partial albinism phenotype. In our cohort, 15% of affected 
individuals had a molecular genetic diagnosis involving the pathogenic haplotype. Consequently, 
the prevalence of albinism seems to be substantially underestimated, and children with unexplained 
bilateral subnormal vision and/or nystagmus should be analysed clinically and molecularly for albinism.
Oculocutaneous albinism (OCA) is a genetically heterogeneous disorder which affects eyes, skin and hair. Six 
genes are known to be associated with OCA: TYR (OCA1), OCA2 (OCA2), TYRP1 (OCA3), SLC45A2 (OCA4), 
SLC24A5 (OCA6) and LRMDA (OCA7) which all show autosomal recessive inheritance1. Ocular albinism (OA) 
which only affects the eyes can be caused by mutations in GPR143, which is located on the X-chromosome. 
Autosomal recessive OA (AROA) has been ascribed to either hypomorphic mutations in genes already known to 
be associated with OCA or mutations in genes not yet known to be associated with albinism. For all types of albi-
nism, the ocular signs are nystagmus, refractive errors, reduced visual acuity, iris hypoplasia, peripheral retinal 
pallor, foveal hypoplasia, and misrouting of the optic pathways. None of these signs, however, are either obligate 
or diagnostic2.
Molecular genetic analysis of the seven genes listed above, provides a genetic diagnosis in approximately half 
of the cases. This leaves relatively many affected individuals without a genetic diagnosis and an unexpectedly 
large proportion of these are heterozygous for mutations in TYR. With the implementation of Next Generation 
Sequencing (NGS), it has become possible to investigate non-coding regions of the genes and perform copy num-
ber variation (CNV) analysis.
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Results
NGS analysis. An overview of the workflow is depicted in Fig. S1. To search for the missing mutations, 
the genomic region of TYR was sequenced in 15 individuals with albinism of whom 12 were heterozygous for a 
mutation in TYR and three were heterozygous for a mutation in both TYR and OCA2 (Fig. S1 box 2; Table S1). 
Data analysis revealed a rare SNV (rs147546939A/G, c.1185-6208A > G) located in intron 3, of which the minor 
allele (G) were present in 11 out of the 15 individuals (Fig. S1 box 3). We further genotyped 78 individuals for 
rs147546939 (Fig. S1 box 4). In total, out of 93 individuals with albinism, 26 were heterozygous and six were 
homozygous for rs147546939G (38/186 alleles, MAF: 0.2043) (Fig. S1 box 3 and 5). This is significantly increased 
compared to both a control group from the Genome Denmark study3 where rs147546939G was found in five out 
of 300 alleles (MAF = 0.0167) (P < 0.0001) and in the gnomAD database (version r2.0.2) where rs147546939G 
is reported in 269 out of 14956 alleles (non-Finnish Europeans, MAF = 0.018) (Tables 1; S1). Noteworthy, 
rs147546939G is exclusively present in individuals with albinism who are either heterozygous for a TYR variant 
(21/58 alleles, MAF = 0.362) or mutation negative (17/94 alleles, MAF = 0.1809) (Fig. S1 box 3 and 5). Therefore, 
rs147546939G is substantially enriched in individuals with albinism and specifically in those with only one iden-
tified pathogenic variant in TYR (P < 0.0001). rs147546939G was not found in any of 32 unaffected family mem-
bers shown to be carriers of a pathogenic TYR variant.
CNV analysis using the NGS data showed no rare deletions or duplications in the region.
Segregation analysis. Six families were analyzed by segregation analysis, and rs147546939G was in trans 
with a pathogenic TYR variant in all six families (Fig. 1A). Results from the segregation analysis combined with 
whole genome sequencing (WGS) of nine OCA individuals (six heterozygous and three homozygous for the 
G allele of rs147546939) (Fig. S1 box 7) showed a common haplotype of 143 SNVs located in chr11:88811249-
89057348 (hg19) (Tables 2 and S2). The haplotype included two rare SNVs (frequency below 2%): rs187887338G, 
located 100 kb upstream from the TYR translation start site, and the already described rs147546939G. A subset 
of individuals had further two very rare SNVs (rs145409367T and rs529155220C), which probably arose later in 
evolution thus resulting in two haplotypes only differing for these two SNVs (Fig. 1; Table S2). We will disregard 
these two SNVs. Two common coding SNVs: rs1042602A p.S192Y (192Y) and rs1126809A p.R402Q (402Q) 
were the only coding SNV’s in the haplotype. Rare or coding SNVs in the haplotype therefore are: rs187887338G, 
rs1042602A (192Y), rs147546939G and rs1126809A (402Q); the haplotype is designated: “GYGQ”.
Functional studies of rs147546939. These results indicate that one or more of the variants shared on the 
haplotypes are pathogenic. Since rs147546939 is located in intron 3 of TYR (c.1185-6208A > G) and deep intron 
variants are known to be potentially pathogenic, this variant was further investigated. Analysis of the sequence 
surrounding rs147546939 showed two potential pseudoexons of 25 bp and 104 bp located immediately down-
stream of the SNV. To investigate if rs147546939G affects splicing and causes inclusion of the pseudoexon, a mini-
gene was constructed. However, due to the large size of intron 3 of TYR (56802 bp) it was not possible to make a 
construct encompassing the full intron, instead, a construct with 1902 bp of intron 3 either with rs147546939G 
or rs147546939A, flanked by part of exon 3 and part of exon 4, was analysed in a minigene construct transfected 
in the TYR expression cell line ARPE-194. Neither the minigene with rs147546939A nor that with rs147546939G 
included the potential pseudoexon (Fig. 2).
Protein modeling. Protein modeling of TYR has previously been proven useful by others5. We therefore 
carried out 3D structure modeling of TYR with 402Q and with 192Y-402Q. This shows that the R402 is posi-
tioned on the surface of the protein in close vicinity of R403, H404, R405, which means that the surface charge 
here is highly positive. The effect of changing the arginine to a glutamine (R402Q) is illustrated Fig. S2A where 
the two top figures represent the wild type (R402), and the two figures below are 402Q. The red circles indicate 
how changing an arginine to a glutamine makes the surface less positive. It is likely that this highly positive patch 
is meant to bind to phosphate, sulfate or other negatively charged groups and that the change to the neutral amino 
acid, glutamine, will affect the ability to do so.
S192 is also positioned on the surface but opposite R402 (Fig. S2B). S192 is positioned in the loops that form 
the entrance of the active site. It is not unlikely that changing the serine with the more bulky tyrosine will hamper 
the entrance to the active site and thereby reduce the activity of the tyrosinase. Indeed the 192Y allele has been 
shown to have 60% of wild type activity6.
SNP
Chr. Position 
(chr 11) Alleles MAFa MAFb
OCA 
cohort
TYR het and 
no mutation
rs187887338 88811249 C/G 0.01130 0.0167 NA NA
rs145409367 88845187 C/T 0.008135 0.0067 NA NA
rs1042602 (p.Ser192Tyr) 88911696 C/A (S/Y) 0.3640 0.31 0.5783 0.7326
rs529135220 88978983 G/C 0.0016 0.0067 NA NA
rs147546939 89011733 A/G 0.01799 0.0167 0.2043 0.2533
rs1126809 (p.Arg402Gln) 89017961 G/A (R/Q) 0.2725 0.28 0.3604 0.4811
Table 1. MAFs rs147546939. (a) Non-Finish Europeans (gnomAD database). (b) Danish ancestry (Genome 
Denmark study).
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Discussion
Many studies of OCA and OA have revealed that a substantial number of cases remain genetically unsolved. A 
considerable number of these are found to be heterozygous for a pathogenic variant in TYR, and the number is 
in excess of that explained by carrier frequency. One variant, 402Q has been subject to extensive discussion over 
the years, and it has been suggested to be pathogenic both on its own as well as when located in cis with 192Y7–11. 
The frequency of 28% in the gnomAD database (non-Finnish Europeans) and the identification of unaffected 
individuals compound heterozygous for a pathogenic variant in TYR and 402Q has excluded that this variant 
on its own is pathogenic. The frequency of 402Q in our cohort was increased in the TYR heterozygous and no 
mutation group (MAF = 0.4811 compared to genome Denmark 0.28) (P < 0.0013). An increased frequency was 
also observed for 192Y which has a MAF of 0.31 in the genome Denmark group compared to 0.7326 in the TYR 
Figure 1. (A) Pedigrees for six families. Haplotypes are shown below each individual. Square indicates male, 
circle indicates female. Filled symbols indicate an individual affected with albinism. M: pathogenic sequence 
variant previously identified in TYR. For each family the specific change are shown above the pedigree. For 
clarity, M is placed on top of the haplotype, but this is not necessarily the actual position. (B) Selected SNVs in 
the haplotype. Chromosomal position are shown on the left, boxes are exons 1, 4 and 5 of TYR, the rs number 
are shown on the right, and on the far right, the two pathogenic haplotypes.
www.nature.com/scientificreports/
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heterozygous and no mutation group (P < 0.00001). Thus, even though the frequencies of 402Q and 192Y are 
increased in individuals with a clinical diagnosis of albinism who are heterozygous for a pathogenic variant in 
TYR or whom have no identified mutation, the frequencies are far too high to be pathogenic. However, a carrier 
frequency of 1.9% of the 192Y-402Q allele in a population of European ancestry has been reported7, and even 
though this frequency also seems high, we suggest that the 192Y-402Q allele is pathogenic (discussed below).
We present a pathogenic haplotype, in which pathogenic variant(s) are expected to be found among the shared 
variants, which are either rare or coding (GYGQ). The haplotypes segregate according to an autosomal recessive 
inheritance pattern and furthermore, have not been observed in unaffected carriers of a TYR mutation. Since the 
rare alleles of rs145409367 and rs529155220 are not present in all individuals these probably have arisen later 
in evolution and it is therefore unlikely that these SNPs are pathogenic. The deep intron variant rs147546939G 
was investigated by minigene analysis and demonstrated to have no effect. However, the drastic reduction in the 
size of TYR intron 3 in the minigene construct could affect the result, and we cannot completely exclude this 
variant as pathogenic. rs187887338G is located 100 kb upstream of the TYR translation in a region not evolu-
tionary conserved and not known to possess enhancers. Thus, we have no data that indicate that rs187887338G 
or rs147546939G are pathogenic. The two coding variants, 192Y and 402Q have previously been suggested to 
be pathogenic when located in cis7,8. The study by Jagirdar et al.7 shows that in human melanocytes with gen-
otype 402Q/Q the tyrosinase is retained in the endoplasmic reticulum (ER). The 192Y allele has been shown 
to have 60% of wild type activity6. It is plausible that the 192Y-402Q allele would result in a substantial amount 
ID rs1878 rs1454 S192Y rs5291 rs1475 R402Q
TYR 
mutation Diagnosis
22 G/G C/C A/A (Y/Y) G/G G/G A/A (Q/Q) No mutation AROA
96 G/G C/T A/A (Y/Y) G/C G/G A/A (Q/Q) No mutation AROA
308 G/G C/T A/A (Y/Y) G/C G/G A/A (Q/Q) No mutation AROA
288 C/G C/C C/A (S/Y) G/G A/G A/A (Q/Q) c.1075C > T OCA
44 C/G C/T C/A (S/Y) G/C A/G A/A (Q/Q) c.228C > G OCA
284 C/G C/C C/A (S/Y) G/G A/G G/A (R/Q) c.1467dupT OCA
112 C/G C/T C/A (S/Y) G/C A/G G/A (R/Q) c.1467dupT OCA
236 C/G C/T A/A (Y/Y) G/C A/G G/A (R/Q) c.915C > A AROA
271 C/C C/C C/A (S/Y) G/G A/A G/G (R/R) c.915C > A AROA
Table 2. WGS of nine individuals. Haplotypes and clinical diagnosis. Y: tyrosine, S: serine, Q: glutamine, R: 
arginine, OCA: oculocutaneous albinism, AROA: autosomal recessive ocular albinism.rs1878: rs187887338, 
rs1454: rs145409367, S192Y: rs1042602, rs5291: rs529135220, rs1475: rs147546939, R402Q: rs1126809.
Figure 2. Minigene analysis of rs147546939. (A) The construct used for transfection. The blue boxes are exon 
sequences of TYR; 3: 91 bp of exon 3; 4: 47 bp of exon 4. The green box indicates the position of rs147546939, 
WT: rs147546939A and MUT: rs147546939G. The orange box indicates the pseudoexon. (B) Transfection 
of constructs in ARPE cells. Both constructs show inclusion of the 79 bp pseudoexon located several kb 
downstream of rs147546939 in the normal endogenous TYR. The identity of the bands was investigated by 
sequence analysis.
www.nature.com/scientificreports/
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of tyrosinase being retained in the ER due to 402Q, and further, that the tyrosinase released from the ER has 
only 60% of wild type activity due to 192Y. This could lower the available tyrosinase activity to a level that is 
pathogenic.
Comparison of individuals with two pathogenic TYR sequence variants with individuals who are compound 
heterozygous for the haplotype GYGQ and a pathogenic TYR sequence variant, shows a more severe phenotype 
in the former group (35 of the 37 had a clinical diagnosis of OCA compared to 15 out of 21 in the latter group; the 
remaining six has a clinical diagnosis of OA or AROA). Furthermore, the six individuals homozygous for GYGQ, 
are all from the no mutation group (N = 47). Five of the six individuals were clinically diagnosed with AROA, and 
thus had a mild albinism phenotype (Table 3). Jagirdar et al.7 found two individuals homozygous for 192Y-402Q 
who showed hypopigmentation, however no ophthalmological data were available. Thus it seems that homozygo-
sity for GYGQ causes a mild albinism phenotype.
The frequency of 192Y-402Q of 1.9% is comparable to the frequency of rs187887338G (MAF: 0.011) and 
rs147546939G (MAF: 0.018) in non-Finnish Europeans. This carrier frequency is surprisingly high if homozy-
gosity for GYGQ causes an albinism phenotype. However, mild albinism might go undetected in a lightly pig-
mented population, as seen by the study of Sjöström et al.12 of the Swedish population, who found a prevalence of 
albinism of about 1% using iris translucency and asymmetric VEP as clinical criteria. This is in contrast to a study 
of children of Mexican origin where a prevalence of 0.3% was found13, and interestingly, the GYGQ haplotype 
is much less frequent in Latino population as indicated by the lower frequency of rs187887338G (MAF: 0.006) 
and rs147546939G (MAF: 0.008). We cannot completely rule out the possibility of an as yet undetected mutation 
linked to the GYGQ haplotype, however, WGS of nine individuals showed no other mutations including CNVs 
(deletions or duplications).
In future studies, it would be relevant to introduce the 192Y-402Q allele on a different haplotype background 
than the one described in this study, and measure the tyrosinase activity, however, this is out of scope for this 
study.
In conclusion, we report a pathogenic haplotype GYGQ in TYR, which may explain 15% of individuals with 
albinism in our cohort. The haplotype seems to result in a mild phenotype both when in trans to a pathogenic 
mutation in TYR and when homozygous. Our results indicate that the prevalence of albinism in European 
descendants is underestimated, and albinism should be considered as a diagnosis in children with subnormal 
visual acuity and/or otherwise unexplained nystagmus.
Methods
Subjects and clinical examinations. Ninety-three individuals were selected from a cohort of 177 indi-
viduals with a clinical diagnosis of albinism (OCA, AROA or OA) (Table S1, Fig. S1). All individuals were of 
Scandinavian descent. Most individuals were examined at a National, ophthalmological diagnostic and rehabili-
tation centre and selected on the basis of the presence of either congenital nystagmus or a visual acuity below 0.3 
or both. We used semi-quantitative phenotype assessment to classify patients as either OCA or AROA. In brief, 
the diagnostic criteria for albinism included nystagmus, reduced visual acuity, iris translucency, fundus hypop-
igmentation, and foveal hypoplasia. Crossed asymmetry of the retino-cortical projections (misrouting) was used 
as an additional sign if present.
The project was approved by The National Committee on Health Research Ethics (Denmark). The project was 
performed according to the Declaration of Helsinki and approved by the Regional Ethics Committee. Written 
informed consent was obtained from all the participants and if under the age of 18 from a parent or legal guard-
ian, before the molecular genetic testing.
DNA sequence analysis. Genomic DNA was extracted from peripheral blood using standard protocols. 
Individuals were subject to molecular genetic analysis either by Sanger sequencing sequentially of the genes TYR, 
OCA2, TYRP1, SLC45A2, LRMDA and GPR143 or by a NGS panel (TYR, OCA2, TYRP1, SLC45A2, LRMDA, 
GPR143, AP3B1, BLOC1S3, BLOC1S6, DTNBP1, HPS1, HPS3, HPS4, HPS5, HPS6, LYST, MITF, MLPH, MYO5A, 
RAB27A, SLC38A8).
Fifteen individuals were selected for targeted NGS analysis of the genomic regions of TYR (chr11:88900000-
89031900, hg19). Targeted libraries for NGS were prepared using Haloplex capture technology (Agilent, Santa 
Clara, CA, USA). The enriched DNA libraries were sequenced using the MiSeq platform (Illumina, San Diego, 
CA, USA). The reads were processed using the SureCall program (Agilent), for alignment to the human genome 
(GRCh37/hg19) with Burrows-Wheeler Aligner (BWA-MEM) and variant calling (SNPPET).
Sample 
ID
rs1042602 
(S192Y)
rs1126809 
(R402Q) rs147546939A > G rs529135220G > C Diagnosis
22 A/A (Y/Y) A/A (Q/Q) G/G G/G AROA
57 A/A (Y/Y) A/A (Q/Q) G/G NA AROA
70 A/A (Y/Y) A/A (Q/Q) G/G NA AROA
96 A/A (Y/Y) A/A (Q/Q) G/G G/C AROA
262 A/A (Y/Y) A/A (Q/Q) G/G NA OCA
308 A/A (Y/Y) A/A (Q/Q) G/G G/C AROA
Table 3. Haplotypes and clinical diagnosis of six individuals with no previously identified mutations in TYR Y: 
tyrosine, Q: glutamine, OCA: oculocutaneous albinism, AROA: autosomal recessive ocular albinism.
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To improve coverage, nine individuals were further analysed by whole genome sequencing and data analysis 
of the TYR genomic region (chr11:88811249-89057348). Genomic DNA was fragmented by an ultrasonicator, 
purified, blunt ended, ‘A’ tailed, and adaptor ligated. DNA templates with adapters were enriched using PCR and 
the concentrations of the libraries were determined. The libraries were sequenced on the Illumina HiSeq platform 
using paired-end reads according to Illumina manufacturer’s instructions (Illumina). The reads were processed 
following the Genome Analysis Toolkit (GATK) (https://www.broadinstitute.org/gatk/guide/best-practices). 
The reads were mapped to the human reference genome (GRCh37/hg19) with BWA, duplicate reads removed 
by Picard tools (https://broadinstitute.github.io/picard/), variants were called by the HaplotypeCaller of GATK 
3,7,8,10.
CNV analysis. The Copy Number Variants (CNVs) were called using the CNVnator read-depth algorithm14. 
The algorithm divides the genome into non overlapping bins of equal size and uses the count of mapped reads in 
each bin as the Read-Depth signal. We used standard settings and a bin size of 100 bp.
Genotyping of rs147546939, rs529135220, rs187887338 and rs145409367. Analysis of 
rs147546939, rs529135220 and rs187887338 was performed by PCR analysis followed by Sanger sequenc-
ing using BigDye terminator v3.2 and analysis on an ABI3100XL platform. Primers used for PCR were as 
follows: rs147546939: Rs147546939-FH acc cac tgc tta ctg gct tat cAG GGC AGA AAA CTT CAC CAA 
and Rs147546939-RH gag ggg caa aca aca gat ggc TCA ACA TGG TTC TTT AAT GTC CAC; rs529135220: 
TYR-c1184-17845-FH acc cac tgc tta ctg gct tat cGG CGG ATT ATG AGG TCA GGA and TYR-c1184-7845-RH 
gag ggg caa aca aca gat ggc TTT GGC CCA CTG TTT GTT CC; rs187887338: TYR-s187887338-FH acc cac 
tgc tta ctg gct tat cTC TCG CTC ATA GGT GGG AAC and TYR-s187887338-RH gag ggg caa aca aca gat ggc 
CCA TGA AAT CTT TGG GGC ACA. Bases in lower case letters were used for sequencing and are not gene 
specific. Analysis of rs145409367 was performed by PCR using primers TYR-s145409367-FH acc cac tgc tta ctg 
gct tat cTG GAT TTG GCA AAG GTG TTT T and TYR-s145409367-RH gag ggg caa aca aca gat ggc TGA ATC 
CTA CTA ATC CAA TGG CT followed by restrictionenzyme analysis with HpyCH4IV (New England Biolabs, 
Ipswich, MA, USA) which only cuts the C allele (major allele).
Minigene analysis. A wild type and a mutant TYR minigene carrying the rs147546939 mutation was con-
structed and cloned into pcDNA3.1 by Genscript. The minigene contains TYR exon 3 (91 bp), 1902 bp of intron 3 
and exon 4 (47 bp). Due to its large size, intron 3 was size-reduced. The minigenes were transfected in duplicates 
into ARPE-19 cells, which are known to express TYR. RNA was isolated and used as template for cDNA synthesis. 
The splicing of TYR intron 3 was examined by PCR using primers TYR1S AAC TTA AGC TTG GTA CCT TGC 
ACA TC and TYR2AS GCC TTC GGA GCC ACT GCT C and subsequently analyzed by agarose gel electropho-
resis. The splicing of the TYR minigene was quantified using the fragment analyzer (Advanced Analytical AATI).
Protein modeling. We modelled the three-dimensional structure of the human tyrosinase protein to predict 
the effect of the S192Y and the R402Q mutations on protein structure/function. The human tyrosinase related 
protein 1 (TYRP1) (PDB entry 5mq8_A)15, which has a sequence identity with human tyrosinase of 44.37% was 
chosen as the best template for a homology model using an automatic run of SWISS-MODEL16. The resulting 
structure was investigated using Pymol17.
Statistics. Fisher’s exact test, two tailed, was performed to test for significance.
References
 1. Grønskov, K., Ek, J. & Brondum-Nielsen, K. Oculocutaneous albinism. Orphanet journal of rare diseases 2, 43 (2007).
 2. Montoliu, L. et al. Increasing the complexity: new genes and new types of albinism. Pigment cell & melanoma research 27, 11–18 
(2014).
 3. Maretty, L. et al. Sequencing and de novo assembly of 150 genomes from denmark as a population reference. Nature 548, 87 (2017).
 4. Mannermaa, E. et al. Filter-cultured arpe-19 cells as outer blood–retinal barrier model. European Journal of Pharmaceutical Sciences 
40, 289–296 (2010).
 5. Balu, K. & Purohit, R. Mutational analysis of tyr gene and its structural consequences in oca1a. Gene 513, 184–195 (2013).
 6. Chaki, M. et al. Molecular and functional studies of tyrosinase variants among indian oculocutaneous albinism type 1 patients. The 
Journal of investigative dermatology 131, 260–262 (2011).
 7. Jagirdar, K. et al. Molecular analysis of common polymorphisms within the human tyrosinase locus and genetic association with 
pigmentation traits. Pigment cell & melanoma research 27, 552–564 (2014).
 8. Norman, C. S. et al. Identification of a functionally significant tri-allelic genotype in the tyrosinase gene (tyr) causing hypomorphic 
oculocutaneous albinism (oca1b). Scientific reports 7, 4415 (2017).
 9. Toyofuku, K. et al. Oculocutaneous albinism types 1 and 3 are er retention diseases: mutation of tyrosinase or tyrp1 can affect the 
processing of both mutant and wild-type proteins. The FASEB Journal 15, 2149–2161 (2001).
 10. Tripathi, R. K., Giebel, L. B., Strunk, K. M. & Spritz, R. A. A polymorphism of the human tyrosinase gene is associated with 
temperature-sensitive enzymatic activity. Gene expression 1, 103–110 (1991).
 11. Lasseaux, E. et al. Molecular characterization of a series of 990 index patients with albinism. Pigment cell & melanoma research 
(2018).
 12. Sjöström, A., Kraemer, M., Ohlsson, J. & Villarreal, G. Subnormal visual acuity syndromes (svas): albinism in swedish 12–13-year-
old children. Documenta ophthalmologica 103, 35–46 (2001).
 13. Sjöström, A. et al. Subnormal visual acuity (svas) and albinism in mexican 12–13-year-old children. Documenta ophthalmologica 
108, 9–15 (2004).
 14. Abyzov, A., Urban, A. E., Snyder, M. & Gerstein, M. Cnvnator: an approach to discover, genotype, and characterize typical and 
atypical cnvs from family and population genome sequencing. Genome research 21, 974–984 (2011).
 15. Lai, X., Wichers, H. J., Soler-Lopez, M. & Dijkstra, B. W. Structure of human tyrosinase related protein 1 reveals a binuclear zinc 
active site important for melanogenesis. Angewandte Chemie International Edition 56, 9812–9815 (2017).
 16. Waterhouse, A. et al. Swiss-model: homology modelling of protein structures and complexes. Nucleic acids research (2018).
 17. Schrödinger, LLC. The PyMOL molecular graphics system, version 1.8 (2015).
www.nature.com/scientificreports/
7SCienTifiC REPORTS |           (2019) 9:645  | DOI:10.1038/s41598-018-37272-5
Acknowledgements
We would like to thank the patients and their families who participated in this study. We thank Pia Skovgaard 
for technical assistance. This work were funded by Fight for sight Denmark and The Danish Eye Research 
Foundation.
Author Contributions
K.G., T.R., K.B.N. and B.S. conceived the experiments, T.R. carried out clinical investigation of the patients and 
collected samples, K.G., C.J. and G.H.B. conducted the experiments, P.H. performed the protein modeling, K.G., 
T.R., K.B.N. and B.S. analyzed the results. K.G. drafted the manuscript. All authors reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-37272-5.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
